

We claim:

1. A recombinant antibody, comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22, wherein the antibody specifically binds to TNF-like ligand 1A (TL1A).
2. The recombinant antibody according to claim 1, wherein the antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3).
3. The recombinant antibody according to claim 1, wherein the antibody is a monoclonal antibody.
4. A composition, comprising the recombinant antibody of claim 1 and a pharmaceutically acceptable carrier, wherein the composition is formulated for administration to a human subject.
5. The recombinant antibody according to claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3.
6. The recombinant antibody according to claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
7. The recombinant antibody according to claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
8. The recombinant antibody according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:60.

9. The recombinant antibody according to claim 1, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:61.
10. The recombinant antibody according to claim 6, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 60.
11. The recombinant antibody according to claim 5, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 61.
12. The recombinant antibody according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain comprising the amino acid sequence of SEQ ID NO: 61.
13. The recombinant antibody according to claim 1 wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 43.
14. The recombinant antibody according to claim 1, wherein the antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 48.
15. The recombinant antibody according to claim 1, wherein the antibody comprises a human IgG1 heavy chain constant region and a human light chain lambda constant region.
16. The recombinant antibody according to claim 6, wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:43.
17. The recombinant antibody according to claim 11, wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:43.
18. The recombinant antibody according to claim 5, wherein the antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO:48.

19. The recombinant antibody according to claim 8, wherein the antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO:48.
20. A transformed host cell that comprises a polynucleotide encoding the antibody according to claim 1 and which expresses said antibody.
21. A method of making an antibody comprising culturing the host cell according to claim 20.
22. An *in vitro* method of detecting TL1A in a sample obtained from a subject comprising contacting the sample with the antibody of claim 1 and detecting the antibody bound to TL1A in the sample.
23. A polynucleotide comprising a nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3.
24. A host cell comprising a vector comprising the polynucleotide of claim 23.
25. A polynucleotide comprising a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
26. A host cell comprising a vector comprising the polynucleotide of claim 25.
27. The host cell of claim 26 further comprising a polynucleotide comprising a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
28. The recombinant antibody according to claim 1, wherein the antibody comprises a human IgG1 heavy chain constant region.
29. The recombinant antibody according to claim 28, wherein the human IgG1 heavy chain constant region comprises SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, or SEQ ID NO: 66.

30. The recombinant antibody according to claim 1, wherein the antibody comprises a human heavy chain IgG4 constant region.
31. The recombinant antibody according to claim 30, wherein the human heavy chain IgG4 constant region comprises SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, or SEQ ID NO: 69.
32. The recombinant antibody according to claim 1, wherein the antibody comprises a human heavy chain IgG2 constant region.
33. The recombinant antibody according to claim 32, wherein the human heavy chain IgG2 constant region comprises SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 70, or SEQ ID NO: 71.
34. The recombinant antibody according to claim 1, wherein the antibody comprises a human light chain lambda constant region.
35. Use of a composition comprising the recombinant antibody of claim 1 and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating a respiratory tract disease selected from asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary sarcoidosis, allergic rhinitis, and cystic fibrosis, wherein the medicament is formulated for administration to a human subject.
36. The use of claim 35 for treating asthma.
37. Use of a composition comprising the recombinant antibody of claim 1 and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating a gastrointestinal disease selected from inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, irritable bowel syndrome, and gastrointestinal disease associated with cystic fibrosis, wherein the medicament is formulated for administration to a human subject.

38. Use of a composition comprising the recombinant antibody of claim 1 and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating arthritis, wherein the medicament is formulated for administration to a human subject.
39. The use of claim 38, wherein the arthritis is rheumatoid arthritis.
40. Use of a composition comprising the recombinant antibody of claim 1 and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating a skin disease selected from atopic dermatitis, eczema, and scleroderma, wherein the medicament is formulated for administration to a human subject.